MEDVi vs ShedRx (2026): prices, structure, verdict

On tirzepatide, ShedRx↗ is cheaper: $289 versus $399 a month all-in — a $110 monthly gap, $1,320 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, ShedRx is cheaper: $249 versus $299 a month all-in — a $50 monthly gap, $600 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

MEDVi: the record, condensed

Start with the load-bearing figure: $399 a month, all-in, is what MEDVi charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $399 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #14 of 17 in the verified tirzepatide index — $184/month above the floor (NexLife↗, $215) — and sits $50 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $4,788.

MEDVi’s semaglutide program bills $299 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes MEDVi unusually easy to compare and unusually easy to leave.

To place the number: #18 of 20 verified programs, with the floor $166/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $50 a month. A year at this figure: $3,588 monthly-billed.

Operationally at MEDVi: shipping included; commitment 12-month plan for the lowest rate; cancellation 12-month plan applies to lowest rate; pharmacy not publicly named — ask in writing before paying; states: priced differently in CA/NC on some plans; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the MEDVi page · visit MEDVi ↗

ShedRx: the record, condensed

On tirzepatide, the number that matters at ShedRx is $289 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The structure is tiered: the advertised entry point is $199, but the maintenance figure — the one a full year is actually billed at — is $289. That $90 gap between the ad and the anniversary is the single most important line in this record.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #5 of 17 in the verified tirzepatide index — $74/month above the floor (NexLife, $215) — and sits $160 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Start with the load-bearing figure: $249 a month, all-in, is what ShedRx charges for semaglutide at the 2.4 mg basis. Pricing steps with the dose here: from $175 at entry to $249 at the 2.4 mg basis. Multiply the wrong one of those by twelve and your budget is off by $888 a year, which is why every ranking on this site uses the larger number.

There is no membership line. $249 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #13 of 20 verified programs, with the floor $116/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $100 a month. A year at this figure: $2,988 monthly-billed.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $289 (ShedRx) against $399 (MEDVi). $110 a month sounds survivable; $1,320 a year is a decision.

Structure sharpens the gap: MEDVi’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while ShedRx’s is not — so MEDVi’s number is a ceiling and ShedRx’s advertised entry ($199) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: ShedRx at $249, MEDVi at $299 — a $50 monthly spread that compounds to $600 over a maintenance year and $1,200 over two.

Structure sharpens the gap: MEDVi’s figure is dose-flat (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill the same), while ShedRx’s is not — so MEDVi’s number is a ceiling and ShedRx’s advertised entry ($175) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Translate the $110/month spread into medication: $1,320 a year equals roughly 4.6 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: MEDVi $399/mo month-to-month versus ShedRx $289/mo month-to-month. Same winner on both bases — ShedRx leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: MEDVi $1,197 monthly; ShedRx $867 monthly — best path favors ShedRx by $330. 6 months: MEDVi $2,394 monthly; ShedRx $1,734 monthly — best path favors ShedRx by $660. 12 months: MEDVi $4,788 monthly; ShedRx $3,468 monthly — best path favors ShedRx by $1,320. 24 months: MEDVi $9,576 monthly; ShedRx $6,936 monthly — best path favors ShedRx by $2,640.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: MEDVi $897 vs ShedRx $747 — $150 to ShedRx. 6 mo: MEDVi $1,794 vs ShedRx $1,494 — $300 to ShedRx. 12 mo: MEDVi $3,588 vs ShedRx $2,988 — $600 to ShedRx. 24 mo: MEDVi $7,176 vs ShedRx $5,976 — $1,200 to ShedRx.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: MEDVi publishes “priced differently in CA/NC on some plans”; ShedRx publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: MEDVi — 12-month plan for the lowest rate; 12-month plan applies to lowest rate. ShedRx — none month-to-month; 72-hour notice before the next billing cycle.

Evidence: MEDVi source-verified (captured 2026-08-05); ShedRx source-verified (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full tirzepatide index these two sit at #14 and #5 of 17: between them lie 8 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #18 and #13 of 20: between them lie 4 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between MEDVi and ShedRx

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (MEDVi: 12-month plan applies to lowest rate; ShedRx: 72-hour notice before the next billing cycle) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings